Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer
Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer
复制标题
DOI：
10.21873/anticanres.16139
复制
发表时间：
2023-01-01
影响因子：
2
通讯作者：
Nagano, Hiroaki
中科院分区：
文献类型：
--
作者：
Chidimatsu, Hikari;Tsunedomi, Ryouichi;Nagano, Hiroaki
背景/目的：结直肠癌是全球第三大常见癌症，转移性结直肠癌（mCRC）患者预后差，值得迫切关注。我们先前获得了10种mCRC的候选血清生物标志物。本研究的目的是确定mCRC患者治疗前血清C-C基序趋化因子配体7（CCL 7）浓度的预后性能。患者，方法：分别使用ELISA和免疫组化检测mCRC患者血清（n=110）和手术标本（n=85）中CCL 7的蛋白浓度。使用考克斯回归分析、受试者操作特征曲线分析和Kaplan-Meier方法检查蛋白浓度与预后之间的关系。结果如下：血清CCL 7浓度高的患者的总生存期（OS）明显低于血清CCL 7浓度低的患者。间质中CCL 7浓度高的患者的结局明显比浓度低的患者差。高浓度CCL 7组癌胚抗原（CEA）、糖链抗原19-9的浓度显著高于低浓度CCL 7组。单因素和多因素分析显示，血清CCL 7浓度是mCRC的一个重要预后因素。血清CCL和CEA浓度的组合在这方面也是有用的（曲线下面积=0.71）。结论：联合检测治疗前血清CCL 7和CEA水平可作为判断mCRC预后的有效指标。
Background/Aim: Colorectal cancer is the third most common cancer globally , the poor prognosis of patients with metastatic colorectal cancer (mCRC) warrants urgent attention. We previously obtained 10 candidate serum biomarkers for mCRC. Our aim with this study was to determine the prognostic performance of the pre-treatment serum C-C motif chemokine ligand 7 (CCL7) concentration in patients with mCRC. Patients , Methods: Protein concentrations of CCL7 were examined using ELISA and immunohistochemistry for serum (n=110) and surgical specimens (n=85), respectively, of patients with mCRC. The relationship between protein concentration and prognosis was examined using Cox regression analysis, receiver operator characteristic curve analysis and the Kaplan-Meier method. Results: The overall survival (OS) of patients with high concentrations of serum CCL7 was significantly poorer than that of patients with low concentrations. Patients with a high CCL7 concentration in the stroma had significantly poorer outcomes than those with a low concentration. The concentrations of carcinoembryonic antigen (CEA) , carbohydrate antigen 19-9 were significantly higher in the high-CCL7 group, compared to those in the low-CCL7 group. Univariate and multivariate analysis revealed that serum CCL7 concentration was a significant prognostic factor for mCRC. The combination of serum CCL and CEA concentrations was also useful in this regard (area under the curve=0.71). Conclusion: The combined pre-treatment serum levels of CCL7 and CEA are useful prognostic biomarkers for mCRC.